Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Morbid obesity among Crohn's disease patients is on the rise and is associated with a higher rate of surgical complications after ileocolic resection
Publication Year: 2025 Source: Colorectal Dis PMID: 39797390
AIM: Crohn's disease (CD) is regarded as a wasting disease, yet there is a growing population of CD patients with a body mass index (BMI) of 35 and above. The rate of postoperative complications is relatively high in CD patients but might be even higher in CD with morbid obesity …
Rare Enterohepatic Fistula in Crohn's Disease: Case Analysis and Literature Synthesis
Publication Year: 2025 Source: Am J Case Rep PMID: 39797391
BACKGROUND Crohn disease is a chronic inflammatory bowel disease known for causing fistulous tracts, abscesses, and bowel perforation. Enterohepatic fistulas, a rare but significant complication, are scarcely reported. This article presents the case of a hepatic abscess due to an enterohepatic fistula in a patient with long-term Crohn disease and …
Colon-Targeted Ginseng Polysaccharides-Based Microspheres for Improving Ulcerative Colitis via Anti-Inflammation and Gut Microbiota Modulation
Publication Year: 2025 Source: Adv Healthc Mater PMID: 39797462
Natural plant-derived polysaccharides exhibit substantial potential for treating ulcerative colitis (UC) owing to their anti-inflammatory and antioxidant properties and favorable safety profiles. However, their practical application faces several challenges, including structural instability in gastric acid, imprecise targeting of inflamed regions, and limited intestinal retention times. To address these limitations, pH-responsive, …
Proposal and exploration of a novel score to quantify patient-perceived burden of inflammatory bowel disease under routine care
Publication Year: 2025 Source: Intern Med J PMID: 39797610 DOI: 10.1111/imj.16634
BACKGROUND: The burden of inflammatory bowel disease (IBD) is often reported on from a system or cost viewpoint. We created and explored a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort. AIM: To create and explore a novel patient-perceived burden of disease (PPBoD) score in a …
Engineering Acid-Promoted Two-Photon Ratiometric Nanoprobes for Evaluating HClO in Lysosomes and Inflammatory Bowel Disease
Publication Year: 2025 Source: ACS Appl Mater Interfaces PMID: 39797821 DOI: 10.1021/acsami.4c18731
HClO is considered a potential contributing factor and biomarker of inflammatory bowel disease (IBD). Accurate monitoring of lysosomal HClO is important for further developing specific diagnostic and therapeutic schedules for IBD. However, only rare types of fluorescent probes have been reported for detecting HClO in IBD so far. Herein, an …
Wearable technology in inflammatory bowel disease: current state and future direction
Publication Year: 2025 Source: Expert Rev Med Devices PMID: 39798078 DOI: 10.1080/17434440.2025.2453561
INTRODUCTION: Wearables are electronic devices worn on the body to collect health data. These devices, like smartwatches and patches, use sensors to gather information on various health parameters. This review highlights the current use and the potential benefit of wearable technology in patients with inflammatory bowel disease (IBD). AREAS COVERED: …
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
Publication Year: 2025 Source: Rheumatology (Oxford) PMID: 39798135
OBJECTIVES: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2 years. METHODS: Patients completing week 52 …
A novel interleukin-10 antibody graft to treat inflammatory bowel disease
Publication Year: 2025 Source: Structure PMID: 39798572 DOI: 10.1016/j.str.2024.12.010
Inflammatory bowel disease (IBD) consists of chronic conditions that severely impact a patient's health and quality of life. Interleukin-10 (IL-10), a potent anti-inflammatory cytokine has strong genetic links to IBD susceptibility and has shown strong efficacy in IBD rodent models, suggesting it has great therapeutic potential. However, when tested in …
Postoperative Endoscopic Outcomes in the MESOCOLIC Trial Investigating Mesenteric-Based Surgery for Crohn's Disease
Publication Year: 2025 Source: Gastroenterology PMID: 39798672
No Abstract
Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis
Publication Year: 2025 Source: Gastroenterol Hepatol PMID: 39798847
BACKGROUND: Mesalamine is the first-line drug for treating mild-to-moderate ulcerative colitis (UC); however, some patients develop symptoms of intolerance. Although several desensitization methods have been reported, these desensitization regimens were rather complicated for physicians to prescribe in daily clinical practice; therefore, it has not yet become a major therapeutic option …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide